RxDoctor Payments Data

Rhonda Museums

Family · Baldwinsville, NYNPI 1871553339

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,150 of the $29,409 with a category attached, or 68.5%. Alk-abello, Inc accounts for 83.6% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $11,311, more than ten times the $1,017 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,409in general payments, 2019–2025

Across 210 payments — averaging $140.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alk-abello, Inc$25K
  • Inspire Medical Systems, Inc.$2K
  • Sanofi$541
  • Regeneron Healthcare Solutions, Inc.$539
  • Jazz Pharmaceuticals Inc.$462
  • Optinose US, Inc.$232
  • plus $896 from 14 others

What the payments were for

  • Consulting fees$9803%
  • Speaking & faculty fees$20,15069%
  • Travel & lodging$3,32811%
  • Food & beverage$4,95117%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,409 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$65,258
Medicare patients
290
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdactraMite,d.Farinae-D.Pteronyssinus27$10,272
Epinephrine19$4,224
Azelastine Hcl177$3,481
Fluticasone Propionate188$1,988
Levocetirizine Dihydrochloride183$1,912
Olopatadine Hcl17$823
Ipratropium Bromide44$817
Mometasone Furoate12$645
Montelukast Sodium34$478
Fluocinolone Acetonide Oil13$266
Lidocaine-PrilocaineLidocaine/Prilocaine22$259
Methylprednisolone47$218
Famotidine17$209
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$200
Mupirocin17$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alk-abello, IncOdactra$24,586$10,27227 claims
Hikma Pharmaceuticals USAEpinephrine$29$4,22419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Baldwinsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →